Sevin Rosen Funds is a top-tier venture capital firm, with a track record of funding successful companies since 1981. The partnership has consistently made early-stage investments in pioneering technologies and companies with the potential to create new markets. The partners' broad range of venture and operating experiences in successful technology companies translates into a sustained commitment and contribution to the development of the ventures funded. Compaq, Lotus, Cypress, Cytokinetics, ArQule, SGI, Citrix, and ViroPharma are representative of some of the firm's successful IPOs. The firm has offices in Dallas, Palo Alto, Austin, and San Diego.


H.I.G. Ventures is a leading private equity and venture capital investment firm with more than $1.5 billion of equity capital under management. From offices in Miami, Atlanta, Boston, and San Francisco, H.I.G. Ventures specializes in providing capital to promising early stage technology and healthcare companies. H.I.G. Ventures aligns with management teams and entrepreneurs who take substantial equity positions in their companies, and helps build businesses of significant value over time.



Ventures West Management Inc., a private venture capital investment group, is one of Canada’s leading investors in early-stage technology companies. Since its founding in 1968, Ventures West has formed eight venture capital funds totaling over $700 million and has invested in more than 130 companies. Ventures West has the people, the expertise, and the capital to help entrepreneurs develop emerging technology companies into market leaders. Examples of Ventures West portfolio companies in Biotechnology include Caprion Pharmaceuticals Inc., Celator Pharmaceuticals Inc., Novadaq Technologies Inc., and Oncogenex Technologies Inc.


WRF Capital is the venture investment arm of the Washington Research Foundation, an independent organization founded in 1981 to support research and scholarship at Washington state research institutions. A leading early-stage investor, WRF Capital partners with entrepreneurs, local universities, and research institutions to develop leading technology companies. Examples of WRF Capital's life science companies include Amnis, Corus Pharma, Ekos, Ikaria, Therus, Lumera, Teranode, and Vanson Halosource.



Delphi Ventures is a venture capital firm that has focused on early-stage investing in medical devices and biotechnology for two decades. With more than $850 million in committed capital, Delphi Ventures has funded over 150 companies. More than 90 of Delphi’s portfolio companies have either completed an initial public offering or have been acquired by a leading healthcare corporation.



TPG Biotech is part of the venture capital investment platform of TPG, the global private investment firm. With more than $500 million under management, TPG Biotech targets investments in life science, biotechnology, renewables and medical technology companies. The firm is backed by the resources of TPG with more than $30 billion of assets under management.




Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. Novo Ventures is recognized as a leader within life sciences venture capital. Novo is active in both Europe and North America. The Novo Ventures team consists of four Partners in Copenhagen, one in London and three in San Francisco. With an evergreen structure, Novo A/S annually invests approximately $100-120 million in venture capital into private life sciences companies, and thus acts at a pace comparable to a traditional $400-500 million fund. Novo A/S is not a corporate strategic fund; the group invests for financial rather than strategic returns. In total Novo A/S has more than $20 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S.